<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03269162</url>
  </required_header>
  <id_info>
    <org_study_id>SHDC12016114</org_study_id>
    <nct_id>NCT03269162</nct_id>
  </id_info>
  <brief_title>Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection</brief_title>
  <official_title>The Prognosis Study of Postoperative Non-small-cell Lung Cancer Patients Treated Precisely With the Integrated Traditional Chinese and Western Medicine Based on CTC Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>lihegen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To study the effect of Jinfukang Koufuye combined with chemotherapy on preventing
      relapse and metastasis of early postoperative NSCLC patients. Method: In this
      multicenter、prospective、randomized controlled clinical trial, 144 NSCLC patients with
      complete resection、stage Ib-IIb were randomly divided into Jinfukang Koufuye combined with
      chemotherapy group (treatment group, N=72) and chemotherapy only group (controlled group,
      N=72). Peripheral blood CTCs and immune cells were detect on five different time points:
      after operation、4 chemotherapy cycles were over、12 months after operation、18 months after
      operation、and 24 months after operation. To evaluate the effect of Jinfukang Koufuye combined
      with chemotherapy on the level of peripheral blood CTCs、DFS、immune function、quality of life
      of postoperative patients; and decreasing the side effect of chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival Rate</measure>
    <time_frame>2 years</time_frame>
    <description>From the very beginning of the randomization to the end point when disease relapse or death because of any reason</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Jinfukang + Chemotherapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jinfukang Koufuye</intervention_name>
    <description>30ml per time, tid, po (d6-21, q21)</description>
    <arm_group_label>Jinfukang + Chemotherapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75mg/m2,ivgtt 30mins, d1</description>
    <arm_group_label>Jinfukang + Chemotherapy Group</arm_group_label>
    <arm_group_label>Chemotherapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500mg/m2, ivgtt 30mins, d1</description>
    <arm_group_label>Jinfukang + Chemotherapy Group</arm_group_label>
    <arm_group_label>Chemotherapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75mg/m2, ivgtt &gt;2h, d1</description>
    <arm_group_label>Jinfukang + Chemotherapy Group</arm_group_label>
    <arm_group_label>Chemotherapy Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathology-confirmed diagnosis of primary NSCLC with complete resection, and stage
             IB-IIB

          2. Accept chemotherapy for the first time 6 weeks after operation

          3. Age of 18-75 years old

          4. Eastern Cooperative Oncology Group-PS≤2

          5. N＞1.5×109/L、PLT＞ 100 × 109/L、Hb&gt;100g/dL、Liver and kidney function is normal or
             elevated ≤ 1.5 times

          6. Voluntary participation in the prospective study with signed informed consent

        Exclusion Criteria:

          1. No pathology-confirmed diagnosis patients

          2. Patients with overall survival time&lt;6 months

          3. Patients with Serious diseases like heart、liver、kidney and hematopoietic system at the
             same time

          4. Pregnant or breast feeding patients

          5. Patients with uncontrollable mentally disease

          6. Patients with diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hegen Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>lihegen</investigator_full_name>
    <investigator_title>Director of Oncology Department Longhua Hospital</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

